2-[4,7-Bis(2-amino-2-oxoethyl)-10-(2-oxopropyl)-1,4,7,10-tetrazacyclododec-1-yl]acetamide

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-[4,7-Bis(2-amino-2-oxoethyl)-10-(2-oxopropyl)-1,4,7,10-tetrazacyclododec-1-yl]acetamide
• 英文别名: 2-[4,7-bis(2-amino-2-oxoethyl)-10-(2-oxopropyl)-1,4,7,10-tetrazacyclododec-1-yl]acetamide
• 化学式: C₁₇H₃₃N₇O₄
• 分子量: 399.5
• InChiKey: PUBHVPUSRBGDAB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.3
• 重原子数：
  28
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.76
• 拓扑面积：
  159
• 氢给体数：
  3
• 氢受体数：
  8

文献信息

• [EN] FIBRIN-BINDING COMPOUNDS FOR IMAGING AND TREATMENT<br/>[FR] COMPOSÉS DE LIAISON À LA FIBRINE POUR IMAGERIE ET TRAITEMENT
  申请人：COLLAGEN MEDICAL LLC

  公开号：WO2021081430A1

  公开（公告）日：2021-04-29

  This disclosure relates to compounds of Formula IV: for fibrin imaging, wherein the compounds comprise an imaging or therapeutic radioisotope.

  这项披露涉及到公式IV的化合物：用于纤维蛋白成像，其中化合物包含成像或治疗放射性同位素。
• [EN] AGENTS FOR CLEAVING LABELS FROM BIOMOLECULES IN VIVO<br/>[FR] AGENTS PERMETTANT DE CLIVER IN VIVO DES MARQUEURS LIÉS À DES BIOMOLÉCULES
  申请人：TAGWORKS PHARMACEUTICALS B V

  公开号：WO2020256545A1

  公开（公告）日：2020-12-24

  Disclosed herein are compounds comprising trans-cyclooctene moieties, combinations, and kits that can be used to more quickly remove radionuclides from a subject, preferably a human being. Said compounds, combinations and kits can also be used to increase the tumor-to-blood ratio, or to more rapidly and/or conveniently achieve such an increase, of a label in targeted imaging or targeted radiotherapy in a subject, preferably a human being.

  本文所披露的化合物包括顺-环辛烯基团，组合物和套装，可用于更快地从受试者（最好是人）中清除放射性核素。所述化合物、组合物和套装还可用于增加靶向成像或靶向放射治疗中标记物的肿瘤/血液比率，或更快地和/或更方便地实现这种增加，适用于受试者（最好是人）。
• IMAGING CONTRAST AGENTS AND USES THEREOF
  申请人：Morrow Janet R.

  公开号：US20140193344A1

  公开（公告）日：2014-07-10

  Provided are macrocyclic compounds having a macrocyclic core which has at least one macrocyclic donor and at least one pendant group which has at least one donor group. The macrocyclic compounds can be complexed to Fe(II) and Ni(II). The macrocyclic compounds can be used in imaging methods. For example, the compounds can be used MRI paraCEST contrast agents.

  提供的是具有至少一个大环供体和至少一个带有至少一个供体基团的挂基团的大环化合物的大环核。这些大环化合物可以与Fe（II）和Ni（II）形成络合物。这些大环化合物可以用于成像方法。例如，这些化合物可以用于MRI paraCEST对比剂。
• CONJUGATE OR ITS SALT COMPRISING A GASTRIN-RELEASING PEPTIDE RECEPTOR ANTAGONIST AND USES THEREOF
  申请人：Orano Med

  公开号：EP3973999A1

  公开（公告）日：2022-03-30

  The invention relates to a conjugate or a pharmaceutically acceptable salt thereof, the conjugate being of formula: C-L-A, wherein C is a chelator, L is a linker covalently bound to the chelator and A is a Gastrin-releasing peptide receptor antagonist covalently bound to the linker, characterized in that: - the chelator is of formula: where the dotted line represents the covalent bond to the linker; - the linker is of formula: -β-Ala-β-Ala-; and - the Gastrin-releasing peptide receptor antagonist has the amino acid sequence: -DPhe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2. The invention also relates to the uses of the conjugate or salt thereof.

  本发明涉及一种共轭物或其药学上可接受的盐，该共轭物的结构式为C-L-A，其中 C 是螯合剂，L 是与螯合剂共价结合的连接体，A 是与连接体共价结合的胃泌素释放肽受体拮抗剂，其特征在于： - 螯合剂为式 其中虚线表示与连接体的共价键； - 连接体为式-β-Ala-β-Ala-；以及 - 胃泌素释放肽受体拮抗剂的氨基酸序列为-DPhe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2。 本发明还涉及共轭物或其盐的用途。